Effect of Ramosetron in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT07574320 | Not Yet Recruiting Phase 4 DMC

• 1 other identifier: IRB-DMC/2025/259
• Study Type: interventional
• Target: 76
• Locations: 0 countries
• Sites: N/A

Brief Summary

Irritable bowel syndrome (IBS) tends to be a lifelong disorder and it is often frustrating to both patients and physicians. This study aim of improving symptom control, reducing healthcare burden and upgrading the quality of life of patient with diarrhea predominant IBS-D. Patients of both sex of age group 18-65 years attending gastroenterology outpatient department Dhaka Medical College Hospital (DMCH) meeting the inclusion criteria of Diarrhea predominant irritable bowel syndrome (IBS-D) will be initially enrolled for the study. Their history, clinical examination \& initial investigations will be done. Report will be noted in the standard data sheet. Any alternative diagnosis if proven by clinical examination or laboratory investigation will be excluded from the study. Each patient will go through a run-in period of 7 days. Number of subjects will be recruited according to sample size. Randomization into two groups will be performed by online randomizer websites. One group will receive tablet ramosetron 2.5 mcg one time daily at morning before breakfast while the other group will receive identical looking placebo one tablet once daily at same time. Both groups will be adviced for low FODMAP diet along with lifestyle modification. The tablets will be administered for total 4 weeks. Before starting treatment, each individual will undergo a baseline assessment during which demographic data, base line investigations, IBS symptoms by IBS Symptom Severity Score (IBS-SSS) will be recorded. Patients will be followed-up after 4 weeks and 8 weeks by IBS-SSS questionnaire. Any adverse effect will be reported quickly and documented at the same time. IBS-SSS is a 5 item tools. It is primarily measures the IBS symptoms which includes abdominal pain and distension as well as bowel satisfaction. This scale evaluates IBS symptoms: abdominal pain, abdominal distension, stool frequency and consistency and interference with life in general. The IBS-SSS calculates the sum of these 5 items scored on a visual analogue scale from 0-100.

Conditions

IBS-D (Diarrhea-predominant)

Keywords

IBS-D; Diarrhea Predominant Irritable Bowel Syndrome; Ramosetron; IBS-SSS

Outcome Measures

Primary Outcomes (1)

• Improvement of diarrhea predominant IBS symptoms

  The improvement of IBS symptoms will be assessed by IBS symptom severity score (IBS-SSS). This score is a Likert scale with seven domains divided into two parts. Part one is the severity score containing four domains, where domain one has two separate scoring scale. Each scale scoring from 0 to 100, that makes it a total score of 500. The severity is denoted as Mild (Score 75 to 175), Moderate (Score 176 to 300), and severe (Score more than 300). The part two is a descriptive questionnaire about bowel habit

  At baseline before randomization and then at week 4 and week 8

Secondary Outcomes (4)

• The effect of ramosetron in diarrhea predominant IBS patients

  At baseline before randomization and then at week 4 and week 8

• The effect of placebo in diarrhea predominant IBS patients

  At baseline before randomization and then at week 4 and week 8

• Compare the effect of ramosetron and placebo

  At baseline before randomization and then at week 4 and week 8

• Adverse events

  through study completion, approximately 1 year

Study Arms (2)

Ramosetron 2.5 microgram

EXPERIMENTAL

Group A - Ramosetron 2.5 microgram

Drug: Ramosetron 2.5 microgram

Placebo

PLACEBO COMPARATOR

Group B - Placebo

Drug: Placebo

Interventions

Ramosetron 2.5 microgram DRUG

Ramosetron 2.5 microgram will be given in Group A

Ramosetron 2.5 microgram

Placebo DRUG

Placebo will be given in Group C

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults aged 18-65 years.
• Patients fulfilling Rome IV diagnostic criteria for IBS-D.
• Willing to provide informed written consent.
• Patients able to attend regular follow-up visits during the study period.

You may not qualify if:

• Presence of alarm features: anemia, weight loss, per rectal bleeding, nocturnal frequency, and family history of colonic cancer or inflammatory bowel disease
• History of major gastrointestinal surgery (excluding appendicitis )
• Recent antibiotic use within 4 weeks
• Patient with uncontrolled diabetes, hyperthyroidism, hypothyroidism
• Pregnant or lactating women
• Drug abuse or alcohol abuse

Sponsors & Collaborators

• Md. Aminul Islam: lead

Central Study Contacts

Dr. Md. Aminul Islam

CONTACT

+8801626299434; aminulthesis0950@gmail.com

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal investigator

Model Details: Phase IV investigator initiated trial with off label dose evaluation

Study Record Dates

• First Submitted: April 22, 2026
• First Posted: May 7, 2026
• Study Start: April 30, 2026
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): February 1, 2027
• Last Updated: May 7, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share